Scottish firm to trial T cells as possible COVID-19 treatment

LONDON (Reuters) - A Scottish biotechnology firm said on Tuesday it would start clinical trials on a possible T cell treatment for COVID-19, aimed at reducing the need for intensive care among hospitalised patients.T cells are white blood cells that form a key part of the immune system, along with antibodies, and scientists are hopeful they could play a role in tackling the novel coronavirus pandemic. TC BioPharm (TCB) said it would conduct the trial at the Edinburgh Royal Infirmary, using..